Trial · NCT00866281
Results by group90
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 90
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) of Midostaurin- Posterior Probability of DLT | Cohort 1: Midostaurin (30 Milligrams/Meters^2) | Younger stratum (≥ 3months -≤ 2 years): (n=2, 5) | 0.03 | 97.5% Confidence Interval 0 to 0.16 | probability estimates |
| Maximum Tolerated Dose (MTD) of Midostaurin- Posterior Probability of DLT | Cohort 2: Midostaurin (60 mg/m^2) | Younger stratum (≥ 3months -≤ 2 years): (n=2, 5) | 0.10 | 97.5% Confidence Interval 0.01 to 0.33 | probability estimates |
| Maximum Tolerated Dose (MTD) of Midostaurin- Posterior Probability of DLT | Cohort 1: Midostaurin (30 Milligrams/Meters^2) | Older stratum (>2 years- <18years): (n=4,6) | 0.03 | 97.5% Confidence Interval 0 to 0.13 | probability estimates |
| Maximum Tolerated Dose (MTD) of Midostaurin- Posterior Probability of DLT | Cohort 2: Midostaurin (60 mg/m^2) | Older stratum (>2 years- <18years): (n=4,6) | 0.08 | 97.5% Confidence Interval 0.01 to 0.26 | probability estimates |
| Percentage of Participants With Best Overall Response by Indication | AML Subjects | Leukemia free state | 0 | Percentage of Participants | |
| Percentage of Participants With Best Overall Response by Indication | MLLr-ALL Subjects | Leukemia free state | 0 | Percentage of Participants | |
| Percentage of Participants With Best Overall Response by Indication | AML Subjects | Morphological complete remission | 0 | Percentage of Participants | |
| Percentage of Participants With Best Overall Response by Indication | MLLr-ALL Subjects | Morphological complete remission | 0 | Percentage of Participants | |
| Percentage of Participants With Best Overall Response by Indication | AML Subjects | Incomplete morphological complete remission | 11.1 | Percentage of Participants | |
| Percentage of Participants With Best Overall Response by Indication | MLLr-ALL Subjects | Incomplete morphological complete remission | 0 | Percentage of Participants | |
| Percentage of Participants With Best Overall Response by Indication | AML Subjects | Partial remission | 0 | Percentage of Participants | |
| Percentage of Participants With Best Overall Response by Indication | MLLr-ALL Subjects | Partial remission | 0 | Percentage of Participants | |
| Percentage of Participants With Best Overall Response by Indication | AML Subjects | Bone marrow blast response | 22.2 | Percentage of Participants | |
| Percentage of Participants With Best Overall Response by Indication | MLLr-ALL Subjects | Bone marrow blast response | 0 | Percentage of Participants | |
| Percentage of Participants With Best Overall Response by Indication | AML Subjects | Bone marrow minor blast response | 0 | Percentage of Participants | |
| Percentage of Participants With Best Overall Response by Indication | MLLr-ALL Subjects | Bone marrow minor blast response | 0 | Percentage of Participants | |
| Percentage of Participants With Best Overall Response by Indication | AML Subjects | Peripheral blood blast response | 11.1 | Percentage of Participants | |
| Percentage of Participants With Best Overall Response by Indication | MLLr-ALL Subjects | Peripheral blood blast response | 23.1 | Percentage of Participants | |
| Percentage of Participants With Best Overall Response by Indication | AML Subjects | Minor peripheral blood blast response | 11.1 | Percentage of Participants | |
| Percentage of Participants With Best Overall Response by Indication | MLLr-ALL Subjects | Minor peripheral blood blast response | 0 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00866281/results